Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
Weight loss without exercise is possible on semaglutide, but the composition of that weight loss changes dramatically
Specification and emulation of the studies To inform our study design and analytic approach for the head-to-head tirzepatide versus semaglutide comparison of interest, we sought to conduct studies that allowed us to benchmark results of similarly designed database studies against results from randomized trials asking closely related questions
The jump from 0.25 mg to 0.5 mg represents a doubling of your dose
Continue until the powder dissolves completely
academic.oup.com/edrv/advance-a Among discussions this week, beyond #weightloss how might GLP-1 address the pathophysiology of #NAFLD #NASH What mechanisms underlie the ESSENCE of the discussion
